Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs known as GLP-1 agonists used to treat people with type 2 diabetes. While some GLP-1 agonists are used for weight loss in ...

Novo Nordisk's Victoza (liraglutide) has become the only approved diabetes drug in the GLP-1 agonist class shown to demonstrate a cardiac safety benefit, although it faces competition from a ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.

insulin use, or molecular structure of GLP-1 agonist agent (semaglutide [Ozempic], liraglutide [Victoza], dulaglutide [Trulicity], or exenatide [Byetta, Bydureon]). There was, however, an inverse ...

Novo Nordisk A/S (NOVO-B.KO) expects its closely-watched diabetes treatment Victoza to reach European customers in the nearest future, Chief Scientific Officer Mads Krogsgaard Thomsen said in an ...

Victoza, Ozempic and Rybelsus accounted for DKr33.2bn in revenue and Saxenda DKr5.7bn. With DKr4.2bn of other diabetes drugs, the diabetes total was DKr102.8bn. Throw in revenue of DKr19.2bn at ...